Compare PepsiCo, Inc. (PEP) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs ResMed Inc. — how do they compare? PepsiCo, Inc. trades at $135.75 (market cap $184.26B), while ResMed Inc. trades at $193.21 (market cap $28.40B). The key difference: PepsiCo, Inc. is far larger — about 6.5× ResMed Inc.'s market cap, and PepsiCo, Inc. pays the higher dividend (4.39%). Which is the better fit depends on your goals.
| PEP | RMD | |
|---|---|---|
Market Cap | $184.26B | $28.40B |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $293.73 |
52-Week Low | $134.98 | $182.82 |
Enterprise Value | $226.76B | $27.58B |
Dividend Yield | 4.39% | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $135.65, up 0.14% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93B in 2025 with a net income margin of 10.78%, and has beaten EPS estimates in three consecutive quarters. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while analysts anticipate Q1 2026 results.
The outlook is mixed: strong profitability and dividend yield near 4% support value, but price sensitivity and debt levels pose risks. Analyst consensus is a $158.79 price target with a 'Hold' bias. Investors should weigh earnings consistency against margin pressures from recent pricing strategies.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
